Fig. 4From: Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylationRosiglitazone activated the phosphorylation of Akt and PKCβ. a HUVECs were treated with rosiglitazone (10 μM) with or without PI3K inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM) simultaneously. Cells were stained with anti-phospho-Akt antibody. b and c Immunoblot analysis for the phosphorylation of Akt and PKCβ (n = 4)Back to article page